바이오테크 보도자료
-
- Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today reported financial result...
- 2021년 03월 12일
-
- ACLIV Wins ISO 21702 Certification for Killing COVID-19 Virus by 99.9% Within 30 Minutes From Antiviral Testing Agency in France
- NEOTENY, a chemical company specializing in film making, announced that it has received ISO 21702 certification (Certification No.: 21-1634) from an antiviral testing agency in France, confirming that its antiviral film ACLIV can kill COVID-19 vir...
- 2021년 03월 12일
-
- Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company pioneering conditionally active bispecific T-cell targeted i...
- 2021년 03월 11일
-
- Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-19
- Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner...
- 2021년 03월 10일
-
- Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
- Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solu...
- 2021년 03월 08일
-
- TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round
- TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH). These strategic investments...
- 2021년 03월 08일
-
- Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseas...
- 2021년 03월 08일
-
- LSK Global PS Adopts Veeva Vault Clinical Applications to Streamline Global Trial Processes
- Veeva Systems (NYSE: VEEV) announced that LSK Global Pharma Services Co. Ltd, a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva SiteVault Free. With Veeva Vault Clinical applications, ...
- 2021년 03월 08일
-
- COVID-19 Vaccine Adjuvant Potentials of Nichi Glucan Dietary Supplement From Japan
- ß- glucan produced by AFO-202 strain of black yeast Aureobasidium Pullulans (Nichi Glucan), having immune enhancement potentials through all major pathways, has been recommended worth clinical studies for validation as a vaccine adjuvant in COVID-...
- 2021년 03월 05일
-
- PierianDx Announces the Appointment of Lindsay Mateo as Chief Business Officer
- PierianDx, the global leader in clinical genomics knowledge, today announced the appointment of Lindsay Mateo as Chief Business Officer, effective immediately. In her new role, Ms. Mateo will reinforce the company’s position as the leading provide...
- 2021년 03월 04일
-
- Rimini Street Announces Fiscal Fourth Quarter and Annual 2020 Financial Results
- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced results for the fourth quar...
- 2021년 03월 04일
-
- Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth[1]
- Regulatory News: Vifor Pharma Group reported stable net sales and a continued strong increase in profitability in 2020, despite challenges to patient access from COVID-19 and the impact of a much stronger Swiss franc against the US dollar. FINANCI...
- 2021년 03월 03일
전시회
